Evaluating Movement Disorders in Children on Risperidone
Author Information
Author(s): Pandina Gahan J, Bossie Cynthia A, Zhu Young, Gharabawi Georges M
Primary Institution: Ortho-McNeil Janssen Scientific Affairs, L.L.C.
Hypothesis
Do objective criteria for assessing movement disorders provide similar rates to spontaneous reports in children receiving risperidone?
Conclusion
Low-dose risperidone was associated with a low risk of tardive dyskinesia and other movement disorders in children with disruptive behavior disorders.
Supporting Evidence
- One patient met the criteria for tardive dyskinesia after a dose reduction.
- Mean ESRS scores were low throughout the study.
- Two subjects reported tardive dyskinesia as an adverse event but did not meet research criteria.
Takeaway
This study looked at kids taking a medicine called risperidone and found that it didn't cause many movement problems, which is good news for their treatment.
Methodology
Data were collected from three one-year, open-label studies assessing movement disorders in children aged 4-14 years receiving risperidone.
Potential Biases
Potential bias due to reliance on spontaneous reporting for adverse events.
Limitations
The open-label design limited comparisons with other antipsychotic agents and lacked historical data on prior medication use.
Participant Demographics
Participants were predominantly male (81.9%) and white (79.8%), with a mean age of 9.4 years and a mean IQ of 64.9.
Statistical Information
P-Value
0.0002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website